4.7 Article

Refining the definition of hypereosinophilic syndrome

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 126, Issue 1, Pages 45-49

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2010.03.042

Keywords

Definition; eosinophilia; eosinophilic leukemia; hypereosinophilic syndromes

Funding

  1. GlaxoSmithKline
  2. AstraZeneca
  3. Roche
  4. CSL Behring
  5. Nycomed
  6. National Institutes of Health
  7. Novartis
  8. Genentech

Ask authors/readers for more resources

Because of advances in our understanding of the hypereosinophilic syndrome (HES) and the availability of novel therapeutic agents, the original criteria defining these disorders are becoming increasingly problematic. Here, we discuss shortcomings with the current definition of HES and recent developments in the classification of these disorders. Despite significant progress in our understanding of the pathogenesis of some forms of HES, the current state of knowledge is still insufficient to formulate a new comprehensive etiologic definition of HESs. Nevertheless, we suggest a new working definition that overcomes some of the most obvious limitations with the original definition. (J Allergy Clin Immunol 2010;126:45-9.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available